Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics expands virus-based cancer treatment patent coverage in the United States

Viralytics expands virus-based cancer treatment patent coverage in the United States

Viralytics Limited (ASX:VLA) has expanded its cancer treatment patent portfolio after a notice of allowance of an additional patent by the US Patent and Trademark Office.

The use of Viralytics' lead product CAVATAK™ is already protected with a portfolio of patents across major world markets, for a number of Group A Coxsackie viruses, which are specific forms of the common cold virus.

This core portfolio covers the use of selected Coxsackie A viruses.

The additional patent in the US broadens patent protection across all Coxsackie A viruses and the wider Group C human enteroviruses that attach to intercellular adhesion molecule-1 in the process of targeting and destroying cancer cells.

CAVATAK™ is injected directly into cancer tumours, and acts to kill both local and metastatic cancer cells by direct cytolysis and a possible immune response.
A notice of allowance indicates the intention to grant a patent after an administrative process is completed.

The United States is the world’s largest pharmaceutical market and broadening patent protection in this market is valuable to Viralytics.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full VLA profile View Profile

Viralytics Timeline

December 10 2015

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use